A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
about
Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsSafety of therapeutic methylphenidate in adults: a systematic review of the evidenceAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementRates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units.Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsInvestigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial.Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder.An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders.Substance-use disorders in adolescents and adults with ADHD: focus on treatment.Treatment of adult ADHD: is current knowledge useful to clinicians?ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetineLimits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective.Prevalence of ADHD among students of zahedan university of medical science in iran.Distinguishing comorbidity and successful management of adult ADHD.Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.Toward quality care in ADHD: defining the goals of treatment.Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review.Addiction in developmental perspective: influence of conduct disorder severity, subtype, and attention-deficit hyperactivity disorder on problem severity and comorbidity in adults with opioid dependence.A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.Barriers to implementation of treatment guidelines for ADHD in adults with substance use disorder.Zur Wirksamkeit pharmakologischer und psychotherapeutischer Therapien bei Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter: Eine empirische Metaanalyse
P2860
Q28246506-BB0BF190-6ADC-45F2-BBF8-ACCA8D174736Q28282264-506A24B4-6251-460F-B779-1EC46C0008F2Q28295525-EB18D022-D27C-4AEE-B17F-18FD4E35C511Q31108345-8615E04B-99D6-403C-8CA1-4B853CEDB9AEQ33919950-3364C47E-FBE4-469F-BBD5-4BE7FA9B64EDQ33957119-A8C1CCCF-DF14-4D69-917F-7418B795E368Q34220004-DEB138EC-D8E4-4AB1-B089-2BA372923FBBQ34714758-BB8E35CA-CFEC-4847-9565-044CDB906E8CQ34763735-1CAE9F22-3915-456A-BC30-895DE8947796Q35878684-751A42CA-8161-4886-A65C-25CF700A2C93Q36344412-4BC05B6F-28D7-428F-AB1A-45D1DFF22141Q36836781-720D3474-808A-4F71-A144-10BA7D11C617Q37056071-6166CD02-2CF0-4FC7-92B4-99F019B4AC06Q37169714-BC59F63D-057A-4E69-9928-EA9177EB2307Q37194205-A1733CF6-B813-40F5-8526-86F64D9C6259Q37505871-E1DD84C5-133F-4AB5-AC31-B3A53AA4F4A7Q37612944-2CAEDBFE-0BCD-4AB4-86A3-7F5725567AF0Q38002290-A4E92345-5FD8-4F85-9DEF-AF3316D3DDDDQ38065287-90FF3540-F604-4A41-9BB8-97385EE527D7Q38082894-56F6B2DA-4B72-46A5-BACB-F8C817D28010Q38241724-F86C492B-E68D-4263-840B-D2ADAE50A1A1Q38243174-F6C46AE9-6985-4EF0-8E89-2F57D098DD68Q38714397-7E2052FF-845F-45E5-BA30-9A54E29C778AQ44333067-17EC0B90-FEB8-4571-AAA2-111895DECFC2Q46713239-983622D5-4891-4DF3-9163-F25E5991ACC5Q52305949-35A0C295-B9E4-4E75-85C0-D91713CFA930Q56962633-F0927869-DEAE-4230-875E-0F090C45D704
P2860
A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A controlled trial of methylph ...... r and substance use disorders.
@en
A controlled trial of methylph ...... r and substance use disorders.
@nl
type
label
A controlled trial of methylph ...... r and substance use disorders.
@en
A controlled trial of methylph ...... r and substance use disorders.
@nl
prefLabel
A controlled trial of methylph ...... r and substance use disorders.
@en
A controlled trial of methylph ...... r and substance use disorders.
@nl
P2093
P2860
P1433
P1476
A controlled trial of methylph ...... er and substance use disorders
@en
P2093
Cor A G Verbrugge
Cor A J de Jong
Pieter J Carpentier
P2860
P304
P356
10.1111/J.1360-0443.2005.01272.X
P407
P577
2005-12-01T00:00:00Z